UCB S.A. UNSP ADR EACH REPR 0.5 ORD News

UCB SA's Dividend Analysis

Yahoo FinanceApr 25 07:04 ET

UCB S.A. UNSP ADR EACH REPR 0.5 ORD To Go Ex-Dividend On April 26th, 2024 With 0.72481 USD Dividend Per Share

April 19th - $UCB S.A. UNSP ADR EACH REPR 0.5 ORD(UCBJY.US)$ is trading ex-dividend on April 26th, 2024. Shareholders of record on April 29th, 2024 will receive 0.72481 USD dividend per share on M

moomoo NewsApr 18 19:40 ET

Ariceum Therapeutics to Present New Radioligand Therapy Data at American Association for Cancer Research (AACR) Annual Meeting 2024

BERLIN, April 4, 2024 /PRNewswire/ -- Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancer

PR NewswireApr 4 03:30 ET

There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target

Tuesday, Longboard Pharmaceuticals Inc (NASDAQ:LBPH) released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of Developmental

BenzingaJan 2 13:55 ET

FDA Approves UCB's Bimzelx for Plaque Psoriasis

Seeking AlphaOct 18, 2023 10:49 ET

UCB Presents Late-breaking Posters at Child Neurology Society Meeting

ATLANTA, Oct. 4, 2023 /PRNewswire/ -- The Child Neurology Society Meeting, a prominent event in the field of pediatric neurology, is set to showcase cutting-edge research and developments in child neurology. As part of

PR NewswireOct 4, 2023 13:06 ET

Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst

Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ:DNTH), a recent reverse merger with the old Magenta Therapeutics. The analysts initiate with an Outperform rating and a price targ

BenzingaSep 28, 2023 15:33 ET

EMA Advisors Recommend Many New Meds at Latest Meeting

Seeking AlphaSep 15, 2023 11:05 ET

Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts

Needham initiated coverage on MoonLake Immunotherapeutics (NASDAQ:MLTX) with a Buy rating and a price target of $76. The analysts Serge Belanger and Rohit Bhasin note the company's lead product devel

BenzingaAug 31, 2023 13:38 ET

FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults

The FDA approved UCB SA's (OTC:UCBJF) (OTC:UCBJY) Rystiggo (rozanolixizumab-noli) for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or anti-muscle-sp

BenzingaJun 27, 2023 13:47 ET

ClearPoint Neuro in Pact With UCB for Gene Therapy Delivery

Seeking AlphaMay 24, 2023 10:25 ET

Veeva in Pact With Belgian Biopharma UCB for Tech-driven Clinical Trials

Seeking AlphaMay 23, 2023 07:40 ET

MoonLake Immunotherapeutics a New Buy at Guggenheim on Sonelokimab

Seeking AlphaMay 1, 2023 10:58 ET

MoonLake Rises 11% as Wedbush Adds to Best Ideas List

Seeking AlphaApr 24, 2023 13:03 ET

Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path

Cantor Fitzgerald has initiated coverage on MoonLake Immunotherapeutics AG (NASDAQ:MLTX) with an Overweight rating and a price target of $23. MoonLake's lead program Sonelokimab or SLK (IL-17A & IL-17

Benzinga Real-time NewsFeb 14, 2023 13:02 ET

UCB Drug Meets Main Goals of 2 Phase 3 Trials for Painful Skin Disorder

Seeking AlphaDec 9, 2022 07:51 ET

UCB's therapy gets FDA orphan drug status to treat seizures linked with rare epilepsy

The U.S. Food and Drug Administration granted orphan drug designation to UCB's (OTCPK:UCBJY) (OTCPK:UCBJF) fenfluramine hydrochloride to treat seizures associated with cyclin-dependent kinase-like 5 (

Seeking AlphaJun 8, 2022 06:47 ET

The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More

Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers fo

Benzinga Real-time NewsMay 30, 2022 14:04 ET

First Presentations of Phase 3 Data for Bimekizumab Across the Full Spectrum of Axial Spondyloarthritis to be Shared at EULAR 2022

New data from BE MOBILE 1 and BE MOBILE 2 show that bimekizumab achieved consistent improvements versus placebo in signs and symptoms across the full spectrum of axial spondyloarthritis (axSpA), including non-radiographic axSpA (nr-axSpA) and ankylosing

PR NewswireMay 23, 2022 12:22 ET

UCB Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to be Presented at EULAR 2022

First presentations from the BE OPTIMAL and BE COMPLETE studies evaluating bimekizumab in the treatment of adults with active psoriatic arthritis who were biologic-naïve and TNF-inadequate responders, respectively A higher proportion of patients treat

PR NewswireMay 23, 2022 12:11 ET